University of Galway has welcomed the significant investment in the region by US multinational Dexcom.
Ahead of the announcement by Dexcom of the establishment of a new manufacturing base in Athenry, senior executives from the company visited the University to learn about research activity.
Representatives from Dexcom met with University of Galway professors Fidelma Dunne and Garry Duffy to hear about clinical trials and transformative technologies being developed for diabetes treatment.
Sinead Walsh, BioInnovate Director of Operations, briefed the executives on the BioInnovate Fellowship, a specialist medical device and digital health programme based at University of Galway.
University of Galway Deputy President and Registrar Professor Pól Ó Dochartaigh said: “We are very pleased to have been able to host Barry Regan and Adrian Furey from Dexcom and give them the opportunity to hear first-hand about University of Galway’s focus on the public good in our research and our ambitions to take our work to new heights.”
University of Galway Vice-President Engagement Dr Paul Dodd said: “The significant investment by Dexcom in Galway is testament to the region as a global medtech hub; a region which University of Galway is at the heart of with our ambitions for investment in research, our excellence in teaching and learning and our desire to ensure the highest standards of graduates.
“We wish Dexcom every success with the investment and we look forward to further developing our engagement in the future.”
